Printer Friendly

THE LIPOSOME COMPANY APPOINTS VICE PRESIDENT, INTERNATIONAL OPERATIONS

 PRINCETON, N.J., May 5 /PRNewswire/ -- The Liposome Company, Inc. (NASDAQ: LIPO, LIPOZ) has appointed Spiro G. Rombotis to the newly created position of vice president, international operations. He reports to Charles A. Baker, chairman and chief executive officer.
 Mr. Rombotis is responsible for directing the company's business activities outside of the U.S. Initially, his main focus will be developing and implementing commercialization strategies for the company's lead products, including ABLC(TM) and Maitec(TM), in major international markets.
 Mr. Rombotis held a variety of business and marketing positions at Bristol-Meyers Squibb Company since 1988, most recently as vice president, operations, pharmaceuticals, Central & Eastern Europe, and previously as director, International Operations & Strategic Management, Squibb Diagnostics. From 1985 to 1988, he was marketing manager, Europe; and manager, corporate development at Centocor, Inc.
 "As our lead products move closer to commercialization, we will be focusing our attention increasingly on Europe and Asia as potential markets," said Mr. Baker. "Spiro brings to The Liposome Company strong international operations and marketing experience to head up this effort. He will be working very closely with Guenter Ksionski, who recently joined us as vice president, international drug development. Their objective will be to make sure that our products are quickly and successfully launched into important overseas markets. I believe they will serve as an excellent team to accomplish this."
 Mr. Rombotis, who is 34 years old, holds an MBA degree in corporate strategy, hospital administration, and international business from the Kellogg Graduate School of Management, Northwestern University, and a BA in economics and sociology from Williams College. He is fluent in several languages.
 The Liposome Company has four drugs currently in clinical trials. ABLC(TM) is in Phase II/III studies for the treatment of systemic fungal infections; Maitec(TM) (formerly TLC G-65) is in Phase II trials in the U.S. and Phase III trials in Europe for the treatment of Mycobacterium avium-intracellulare (MAI), an infection that eventually strikes 30 to 50 percent of people with AIDS; TLC D-99 is in Phase II for treatment of mestatic breast cancer; and TLC C-53 has completed Phase I trials in preparation for studies in Adult Respiratory Distress Syndrome.
 A leading company dedicated exclusively to the development of liposome and lipid-based pharmaceuticals, The Liposome Company develops proprietary parenteral pharmaceuticals for the treatment, prevention, and diagnosis of
life-threatening diseases. -0- 5/5/93
 /CONTACT: Anne M. Van Lent, senior vice president of The Liposome Company, Inc., 609-452-7060/
 (LIPO)


CO: Liposome Company, Inc. ST: New Jersey IN: MTC SU: PER

TM -- NY006 -- 4711 05/05/93 08:43 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 5, 1993
Words:430
Previous Article:READER'S DIGEST TO PUBLISH NEW EDITION IN CZECH REPUBLIC
Next Article:MCI SELECTED TO MANAGE GLOBAL COMMUNICATIONS NETWORK FOR J.P. MORGAN
Topics:


Related Articles
FORMER MERCK EXECUTIVE APPOINTED TO LIPOSOME COMPANY BOARD OF DIRECTORS
THE LIPOSOME COMPANY APPOINTS NEW MANUFACTURING EXECUTIVE
LIPOSOME COMPANY NAMES SILVERMAN VP OF STRATEGIC PLANNING
A. L. LABORATORIES ANNOUNCES KEY MANAGEMENT APPOINTMENTS AT ITS BARRE-NATIONAL SUBSIDIARY
THE LIPOSOME COMPANY APPOINTS DAVID SHAND TO BOARD OF DIRECTORS
ANDREW JANOFF AND JOEL PORTNOFF NAMED VICE PRESIDENTS AT THE LIPOSOME COMPANY
THE LIPOSOME COMPANY, INC. PROMOTES TWO EXECUTIVES; SILVERMAN, WILLIAMS NAMED TO NEW MANAGEMENT POSTS
THE LIPOSOME COMPANY ANNOUNCES RESEARCH MANAGEMENT REALIGNMENT
THE LIPOSOME COMPANY APPOINTS JOSEPH STEWART TO ITS BOARD OF DIRECTORS
THE LIPOSOME COMPANY ANNOUNCES NEW MANAGEMENT APPOINTMENTS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters